AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 675
- Registration Number
- NCT06357533
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Recruiting
- Conditions
- ATTR Amyloidosis
- Interventions
- Other: no intervention
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55000
- Registration Number
- NCT06355934
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT06357520
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT06350097
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
Phase 2
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 324
- Registration Number
- NCT06350123
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT06348355
- Locations
- 🇸🇪
Research Site, Solna, Sweden
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3
Recruiting
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 589
- Registration Number
- NCT06346392
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 3
Recruiting
- Conditions
- Uncontrolled HypertensionResistant Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06344104
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C)
Phase 1
Not yet recruiting
- Conditions
- Healthy
- Interventions
- Device: AeroChamber Plus Flow-Vu Spacer
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 132
- Registration Number
- NCT06340581
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia
Terminated
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1770
- Registration Number
- NCT06338839
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath